Shineco, Inc.
TYHT
NASDAQ Capital Market11.09
USD
-0.45
- -
CIK
0001300734
ISIN
US8245672006
CUSIP
824567200
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yuying Zhang
- Full Time Employees
- 216
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 515 Madison Ave Ste 2100 Beijing People's Republic of China 100176
- IPO Date
- Sep 26, 2016
- CIK
- 0001300734
- Website
- tianyiluobuma.com
- Similar Companies
- Business
- Shineco, Inc. operates as a holding entity, leveraging its subsidiaries and variable interest structures to engage in various industries. The company, based in Beijing, China, has strategically reoriented its core operations towards advancing health and quality of life through innovative medical and health solutions. Its business framework encompasses several distinct areas: the research, development, and commercialization of sophisticated diagnostic products and associated medical devices; the production and distribution of nourishing and healthy food items; and a significant focus on cutting-edge biotechnology platforms, notably induced pluripotent stem cell (iPSC) technologies and products derived from extracellular vesicles. Historically involved in the cultivation, processing, and distribution of plant-based goods, including specialized textiles from Apocynum Venetum (Luobuma), traditional Chinese medicinal herbs, and organic agricultural produce, Shineco has largely shifted its operational emphasis. The firm now applies modern engineering and biotechnological methods across its integrated production, distribution, and sales channels to deliver high-quality, health-focused offerings to its market. Recent strategic initiatives include forming a Biological Cell Digital Division to integrate cell assets with blockchain technology and securing substantial technology service contracts for advanced biotechnology research and development. The company's common stock, previously traded under the ticker TYHT, now trades on Nasdaq under the symbol SISI.
Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology
Shineco, Inc. to Effect 50:1 Reverse Stock Split
Shineco Announces Acquisition of Medical Device Company
Shineco, Inc. Announces Nasdaq Ticker Symbol Change from "TYHT" to "SISI"
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
TYHT Stock: From $11.94 To $16.23 (35.93% Increase) Explanation